Production (Stage)
Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -85.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -85.71% | |||
| Cost of Revenue | -- | 44,600.00% | |||
| Gross Profit | -- | -26,900.00% | |||
| SG&A Expenses | -52.46% | 49.33% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -88.00% | 487.21% | |||
| Operating Income | 87.99% | -500.67% | |||
| Income Before Tax | -166.93% | 288.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -166.93% | 288.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -166.93% | 288.00% | |||
| EBIT | 87.99% | -500.67% | |||
| EBITDA | 73.04% | -214.00% | |||
| EPS Basic | -168.42% | 290.00% | |||
| Normalized Basic EPS | 68.00% | -316.67% | |||
| EPS Diluted | -168.42% | 290.00% | |||
| Normalized Diluted EPS | 68.00% | -316.67% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||